PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 27(Supplement_2): 289-292
2007
© 2007 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawanishi, H.
Right arrow Articles by Moriishi, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kawanishi, H.
Right arrow Articles by Moriishi, M.

Part 9: Miscellaneous Complications and Pathophysiologic Mechanisms

ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT

Hideki Kawanishi and Misaki Moriishi

Tsuchiya General Hospital, Hiroshima, Japan

Correspondence to: H. Kawanishi, Tsuchiya General Hospital, 3-30 Nakajima-cho, Naka-ku, Hiroshima 730-8655 Japan. h-kawanishi{at}tuschiya-hp.jp

Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered primarily a fatal complication. The incidence of EPS in PD patients has been reported to be 2.5%, with a negative effect of increasing PD duration (which also augments mortality). Because EPS occurs after withdrawal from PD in more than half of all cases, strict monitoring is necessary when a long-term PD patient is withdrawn from PD. Maintaining patients on standard PD with conventional solutions for more than 8 years is associated with a substantial risk of EPS development. Treatment appropriate to the disease stage is most important in EPS. Basic therapeutic strategies for EPS include the appropriate use of steroids. If bowel obstruction persists, laparotomy and enterolysis should be performed to achieve a complete cure. It is now recognized that EPS need not be a fatal complication of PD.

KEY WORDS: Encapsulating peritoneal sclerosis; EPS; peritoneal deterioration; surgical options.




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
O. Devuyst, P. J. Margetts, and N. Topley
The Pathophysiology of the Peritoneal Membrane
J. Am. Soc. Nephrol., July 1, 2010; 21(7): 1077 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
J. Vanmassenhove, R. Vanholder, R. Forsyth, and A. Dhondt
Encapsulating Peritoneal Sclerosis in a Patient with Primary Hyperoxaluria Type 1: a Case Report
Perit. Dial. Int., January 1, 2010; 30(1): 108 - 111.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
S. Guest
HYPOTHESIS: GENDER AND ENCAPSULATING PERITONEAL SCLEROSIS
Perit. Dial. Int., September 1, 2009; 29(5): 489 - 491.
[Full Text] [PDF]

Home page
 pdiHome page
L. Liu, C.-X. Shi, A. Ghayur, C. Zhang, J. Y. Su, C. M. Hoff, and P. J. Margetts
PROLONGED PERITONEAL GENE EXPRESSION USING A HELPER-DEPENDENT ADENOVIRUS
Perit. Dial. Int., September 1, 2009; 29(5): 508 - 516.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2007 by Multimed Inc.